6533b86dfe1ef96bd12c9344

RESEARCH PRODUCT

KRAS-mutated intrahepatic cholangiocarcinoma shows preferential sensitivity towards PARP-1-based interventions

Fl MahnD CastvenSp PereiraM HartmannJ FahrerJb AndersenMs MatterT GaiserS RösslerPr GalleJu Marquardt

subject

business.industryPoly ADP ribose polymeraseCancer researchmedicineSensitivity (control systems)KRASmedicine.disease_causebusinessIntrahepatic Cholangiocarcinomahttps://doi.org/10.1055/s-0039-3402209